2023
Therapeutic efficacy of intravenous infusion of mesenchymal stem cells in rat perinatal brain injury
Terada K, Sasaki M, Nagahama H, Kataoka-Sasaki Y, Oka S, Ukai R, Yokoyama T, Iizuka Y, Sakai T, Fukumura S, Tsugawa T, Kocsis J, Honmou O. Therapeutic efficacy of intravenous infusion of mesenchymal stem cells in rat perinatal brain injury. Pediatric Research 2023, 94: 1921-1928. PMID: 37422495, DOI: 10.1038/s41390-023-02717-9.Peer-Reviewed Original ResearchConceptsPerinatal brain injuryBrain injuryMesenchymal stem cellsIntravenous infusionVehicle groupBrain volumeTherapeutic efficacyInfused mesenchymal stem cellsLeft common carotid arteryHistological analysisNon-ischemic hemispherePostnatal day 7Common carotid arteryEmbryonic day 18Stem cellsHypoxia-ischemiaMSC infusionPreterm infantsGABAergic cellsNeurological functionSignificant complicationsCortical synapsesFunctional improvementCarotid arteryIntravenous administration
2022
Intravenous Infusion of Autoserum-Expanded Autologous Mesenchymal Stem Cells in Patients With Chronic Brain Injury: Protocol for a Phase 2 Trial
Oka S, Yamaki T, Sasaki M, Ukai R, Takemura M, Yokoyama T, Kataoka-Sasaki Y, Onodera R, Ito YM, Kobayashi S, Kocsis JD, Iwadate Y, Honmou O. Intravenous Infusion of Autoserum-Expanded Autologous Mesenchymal Stem Cells in Patients With Chronic Brain Injury: Protocol for a Phase 2 Trial. JMIR Research Protocols 2022, 11: e37898. PMID: 35793128, PMCID: PMC9301565, DOI: 10.2196/37898.Peer-Reviewed Original ResearchChronic brain injuryAutologous mesenchymal stem cellsSpinal cord injuryINTERNATIONAL REGISTERED REPORT IDENTIFIERBrain injuryIntravenous infusionRankin Scale gradesCord injuryMesenchymal stem cellsClinical trialsScale gradeTherapeutic efficacyJapan Medical Association CenterSapporo Medical University HospitalInvestigator-initiated clinical trialsModified Rankin Scale gradesOpen-label trialPhase 2 studyPhase 2 trialMedical University HospitalCause of disabilityMotor vehicle accidentsPotential therapeutic efficacyProportion of casesStem cells
2021
Possible role of intravenous administration of mesenchymal stem cells to alleviate interstitial cystitis/bladder pain syndrome in a Toll-like receptor-7 agonist-induced experimental animal model in rat
Tabata H, Sasaki M, Kataoka-Sasaki Y, Shinkai N, Ichihara K, Masumori N, Kocsis JD, Honmou O. Possible role of intravenous administration of mesenchymal stem cells to alleviate interstitial cystitis/bladder pain syndrome in a Toll-like receptor-7 agonist-induced experimental animal model in rat. BMC Urology 2021, 21: 156. PMID: 34774029, PMCID: PMC8590770, DOI: 10.1186/s12894-021-00923-3.Peer-Reviewed Original ResearchConceptsHunner-type ICBladder pain syndromeAnti-inflammatory pathwayMSC groupMesenchymal stem cellsPain syndromeAnimal modelsToll-like receptor 7 agonistTherapeutic efficacyBehavior testsRight external jugular veinFemale Sprague-Dawley ratsGFP-positive mesenchymal stem cellsReceptor 7 agonistChronic pelvic painAnti-inflammatory effectsEfficacious treatment optionExperimental animal modelsSprague-Dawley ratsExternal jugular veinReal-time polymerase chain reactionMRNA expression levelsPositive mesenchymal stem cellsStem cellsHunner lesions